Yang, N., Luna J.M., Dai, P., Wang, Y., Rice, C.M., and L. Deng. (2022). Lung type II alveolar epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against poxvirus infection. Nat Commun. 13(1):1671. PMID: 35351885. PMCID: PMC896475.
Budhu S, Giese R, Gupta A, … Mazo G, Deng L, Barker CA, Wolchok JD, and Merghoub T (2021). Targeting phosphatidylserine enhances the anti-tumor responses to tumor-directed radiation therapy in a preclinical model of melanoma. Cell Reports 34: 108620.
Wang W., Liu, S., Dai P., YangN., WangY., Giese RA, Merghoub T., WolchokJ.D., and L. Deng (2021). Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated Vaccinia. Journal for ImmunoTherapy of Cancer, 2021;9:e002569. doi:10.1136/jitc-2021-002569.
Yang, N., Garcia, A., Meyer, Tuschl T., Merghoub, T., Wolchok, J.D., and L. Deng (2022) Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. npj Vaccines (2022) 7:120; https://doi.org/10.1038/s41541-022-00542-5.
Yang, N., Wang, Y., Dai, P., Li, T., Zierhut, C., Tan, A., Zhang, Z., Pan, H., Li, Z., Ordureau, A., Xiang, J.Z., Hendrickson, R.C., Funabiki H., Chen, Z., Deng, L. (2021) Vaccinia E5 is a major inhibitor of the DNA sensor cGAS. bioRxiv. doi: https://doi.org/10.1101/2021.10.25.465197. Nature Communications, in revision.
Yang, N., #, Wang, Y.,#, Liu, S., Luna, J. M., MazoG., Tan, A., Zhang, T., Wang, J., Yan, W., Choi, J., Rossi, A., Xiang, J.Z., Rice, C. M., Merghoub,T., Wolchok, J. D., and Deng, L. (2021) Intratumoral delivery of engineered recombinant modified vaccinia virus Ankara expressing Flt3L and OX40L generates potent antitumor immunity through activating the cGAS/STING pathway and depleting tumor-infiltrating regulatory T cells. bioRxiv. Doi: https: //doi.org/10.1101/2021.10.31.466698. Journal Experimental Medicine, In revision.
Liu S.#, Mazo G.#, Yang N., … Merghoub,T., Wolchok, J. D., and Deng, L. (2022) IL-12-expressing highly immunogenic recombinant modified vaccinia virus Ankara reprograms tumor-infiltrating myeloid cells to overcome immune resistance. bioRxiv, 2022.09.25.509429. https://doi.org/10.1101/2022.09.25.509429.
Yan, J., Chen, Y., Patel, A.J., Warda, S., Lee, C.J., Nixon, B.G., Wong, E.W., Miranda-Román, M.A., Deng, L., … & Chi, P. (2022). Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic therapeutic viruses. The Journal of Clinical Investigation, e153437-e153437.
Sahu, A., Kose, K., Kraehenbuehl, L., Byers, C., Holland, A., Tembo, T., …Deng, L., … & Rajadhyaksha, M. (2022). In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. Nature communications, 13(1), 1-19.
Gu, L., Lin, E., Liu, S., Yang, N., Kurtansky, N., Neumann, N., Stoll, J., Lezcano, C., Pulitzer, M., Noor, S., Markova, A., Rossi, A., Dickson, M., and Deng L. (2022) Efficacy of Immunotherapy with Combination of Cryotherapy and Topical Imiquimod for Treatment of Kaposi Sarcoma. Accepted by Journal of Medical Virology.
Yang, N., J.M. Luna, P. Dai, Y. Wang, C.M. Rice, and L. Deng (2020) Lung type II epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against an acute vaccinia infection in the lungs. BioRxiv 10.1101/2020.01.20.910927.
Shaw K.S., G.H. Nguyen, M. Lacouture, and L. Deng. (2017). Combination of imiquimod with cryotherapy for the treatment of penile intraepithelial neoplasia. JAAD Case Rep. 3(6):546-549.
Dai, P., W. Wang, N. Yang, C. Serna-Tamayo, J.M. Ricca, D. Zamarin, S. Shuman, T. Merghoub, J.D. Wolchok, and L. Deng. (2017). Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent DCs. Science Immunology 2, eaal1713: 1-15.
Gao, P., T. Zillinger, W. Wang, M. Ascano, P. dai, G. Hartmann, T. Tuschl, L Deng, W. Barchet, and D.J. Patel. (2014). Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA. Cell Rep 8:1-9.
Dai, P., W. Wang, H. Cao, F. Avogadri, L. Dai, I. Drexler, J. A. Joyce, T. Merghoub, S. Shuman, and L. Deng. Modified vaccinia virus Ankara triggers type I IFN production in conventional dendritic cells via a cGAS/STING-dependent cytosolic DNA-sensing pathway. PLoS Pathogens 2014;10:e1003989.
Kung, G., Dai P., Deng L., and R.N. Kitsis. A novel role for the apoptosis inhibitor ARC in suppressing TNFα-induced regulated necrosis. Cell Death Diff. 2014; 1-11.
Gao, P., M. Ascano, T. Zillinger, W. Wang, P. Dai, A.A. Serganov, B. L. Gaffney, S Shuman, R. A. Jones, L. Deng, G. Hartmann, W. Barchet, T. Tuschl, D. J. Patel. Structure-function analysis of STING activation by c[G(2’,5’)pA(3’,5’)p] and targeting by antiviral DMXAA. Cell 2013; 154, 748-762.
Cao H, Dai P, Wang W, Li H, Yuan J, Wang F, Fang CM, Pitha PM, Liu J, Condit RC, McFadden G, Merghoub T, Houghton AN, Young JW, Shuman S, and Deng L. Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. PLoS One 2012; 7: e36823.
Dai P, Cao H, Merghoub T, Avogadri F, Wang W, Parikh T, Fang CM, Pitha PM, Fitzgerald KA, Rahman MM, McFadden G, Hu X, Houghton AN, Shuman S, and Deng L. Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway. J Virol. 2011; 85: 10814-10825.
Deng L, Dai P, Parikh T, Cao H, Bhoj V, Sun Q, Chen Z, Merghoub T, Houghton AN, Shuman S. Vaccinia virus subverts a mitochondrial antiviral signaling protein-dependent innate immune response in keratinocytes through its double-stranded RNA binding protein, E3. J Virol. 2008; 82:10735-10746.
Mandal S, Wang SQ, Busam K, Heaney ML, Deng L. Multiple erythematous eroded patches and papules on the scalp. Arch Derm 2008; 144:105-110.
Deng L, Dai P, Ciro A, Smee DF, Djaballah H, Shuman S. Identification of novel antipoxviral agents: Mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol. 2007; 81:13392-13402.
Ardigo M, Zieff J, Scope A, Gill M, Spencer P, Deng L, Marghoob A. Dermoscopic and reflectance confocal microscope findings of trichoepithelioma. Dermatology 2007; 215:354-358.
Deng L; Dai P; Ding W; Granstein RD; Shuman S. Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J Virol. 2006; 80:9977-9987.
Deng L, Ding W, Granstein RD. Thalidomide inhibits TNF-α production and immunostimulatory function of Langerhans cells. J Invest Dermatol. 2003:121: 1060-5.
Ding W, Beissert S, Deng L, Miranda E, Cassetty C, Seiffert K, Campton KL, Yan Z, Murphy GF, Bluestone JA, Granstein RD. Altered cutaneous immune parameters in transgenic mice over expressing viral IL-10 in the epidermis. J Clin Invest. 2003; 111: 1923-31.
Deng L, Shuman S. Vaccinia NPH-1, a DExH-box ATPase, is the energy coupling factor for mRNA transcription termination. Genes & Development 1998; 12: 538-546.
Deng L, Shuman S. Elongation properties of vaccinia virus RNA polymerase: pausing, slippage, 3’ end addition, and termination site choice. Biochemistry. 1997; 36: 15892-9.
Yu L, Martins A, Deng L, Shuman S. Structure-function analysis of the triphosphatase component of vaccinia virus mRNA capping enzyme. J Virol. 1997; 71: 9837-43.
Deng L, Shuman S. An ATPase component of the transcription elongation complex is required for factor-dependent transcription termination by vaccinia RNA polymerase. J Biol Chem. 1996; 271: 29386-92.
Deng L, Hagler J, Shuman S. Factor-dependent release of nascent RNA by ternary complexes of vaccinia RNA polymerase. J Biol Chem. 1996; 271: 19556-62.
Luo Y, Mao X, Deng L, Cong P, Shuman S. The D1 and D12 subunits are both essential for the transcription termination factor activity of vaccinia virus capping enzyme. J Virol. 1995; 69: 3852-6.
Deng L, A role for the H4 subunit of vaccinia RNA polymerase in transcription initiation at a viral early promoter. J Biol Chem. 1994; 269: 14323-8.
Deng, L., S. Shuman, J. D. Wolchok, T. Merghoub, P. Dai, and W. Wang. Use of Inactivated Nonreplicating Modified Vaccinia Virus Ankara (MVA) as Monoimmunotherapy or in Combination with Immune Checkpoint Blockade for Solid Tumors. PCT Application No. PCT/US2016/019663/CA2982896. Published on Sep. 15, 2016. Issued.
Deng, L., S. Shuman, J. D. Wolchok, T. Merghoub, P. Dai, and W. Wang. Use of MVA or MVAΔE3L Mutant as an Immunotherapeutic Agent Against Solid Tumors. PCT Application No. PCT/US2016/028184/CA2977660. Published on Oct. 20, 2016. Issued.
Deng, L., S. Shuman, J. D. Wolchok, T. Merghoub, P. Dai, W. Wang, and N. Yang. Replication Competent Attenuated Vaccinia Viruses with Deletion of Thymidine Kinase (VC-TK-) with and without the Expression of human Flt3L for Cancer Immunotherapy. PCT/US2017/019548. WO 2017/147553 A2 Published on August 31, 2017. Issued.
Deng, L., S. Shuman, J. D. Wolchok, T. Merghoub, P. Dai, W. Wang, and N. Yang. Recombinant MVA or MVAdelE3L Expressing Human Flt3L and Use Thereof as Immuno-Therapeutic Agents against Solid Tumors. PCT/US2017/019549. US20190046640A1 Published on Feb. 14, 2019.
Deng, L., N. Yang, S. Shuman, Taha Merghoub, Jedd D. Wolchok. Vaccinia virus mutants useful for cancer immunotherapy. Replication Competent Attenuated Vaccinia Viruses with Deletion of both Thymidine Kinase and Vaccinia C7 (VC-TK-delC7) or Non-replicating MVA or MVAΔE3L with deletion of Vaccinia C7, for cancer immunotherapy. PCT/US2018/032451. WO2018209315A1 Published on Nov. 15, 2018.
Deng, L. W. Yan, W. Wang, P. Dai, N. Yang, S. Shuman, T. Merghoub, J. D. Wolchok Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy. PCT/US2019/021853. WO2019178101A1 published on September 19, 2019.
Deng, L., N. Yang, J. D. Wolchok, T. Merghoub, S. Shuman. Heat-inactivated vaccinia as a vaccine immune adjuvant. PCT/US2018/059476 WO2019090343 published on September 5, 2019.
Deng, L., S. Shuman, J. D. Wolchok, T. Merghoub, P. Dai, and W. Wang. Use of Inactivated Nonreplicating Modified Vaccinia Virus Ankara (MVA) as Monoimmunotherapy or in Combination with Immune Checkpoint Blockade for Solid Tumors. PCT Application No. PCT/US2016/019663/CA2982896; Published on Sept. 15, 2016.
Deng, L., J. D. Wolchok, T. Merghoub, S. Shuman, P. Dai, and W. Wang. Use of MVA or MVAΔE3L Mutant as an Immunotherapeutic Agent Against Solid Tumors. PCT Application No. PCT/US2016/028184/CA2977660; Published on Oct. 20, 2016.